Barclays analyst Stephanie Davis lowered the firm’s price target on Quest Diagnostics to $138 from $145 and keeps an Equal Weight rating on the shares. The company’s Q4 print featured a headline beat offset by softer earnings guidance, the analyst tells investors in a research note. The firm says that while many of the earnings headwinds are known and one-timers, investors will be cautious on the more second half-weighted outlook and continue to view its long-term targets as a “show me” story.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Announces 5.6% Quarterly Dividend Hike
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Notable companies reporting before tomorrow’s open
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quest Diagnostics price target lowered to $152 from $153 at JPMorgan